CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Arcus Biosciences drops after starting stock offering

By Reuters News

** Shares of Arcus Biosciences RCUS.N down 4.4% at $18.26 in extended trading after equity offering news

** Cancer and immune diseases-focused biopharma launches stock offering without disclosing deal size

** Jefferies, Leerink and TD Cowen joint bookrunners

** It intends to use net offering proceeds to fund R&D, including expansion and acceleration of clinical development program for its drug casdatifan, and for other general corporate purposes, per the prospectus

** Hayward, California-based RCUS has ~127.3 mln shares outstanding for ~$2.4 bln market cap

** RCUS stock plunged 19.6% to close at $19.10 on Weds. Shares have fallen 36% over the past three months, leaving them down ~20% YTD

** 13 of 15 analysts rate the stock "strong buy" or "buy", 2 "hold"; median PT $43.50, per LSEG

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk